- Home
- FOFO vs DXR Comparison
FOFO vs DXR Comparison
Compare FOFO & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FOFO | DXR |
|---|---|---|
| Founded | 2017 | 1970 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.2M | 69.1M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | FOFO | DXR |
|---|---|---|
| Price | $5.74 | $12.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 64.6K | 7.4K |
| Earning Date | 03-13-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.46 |
| EPS | ★ 0.36 | 0.36 |
| Revenue | ★ $3,117,608.00 | $66,306.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $15.35 | $35.27 |
| Revenue Growth | ★ 1597.65 | N/A |
| 52 Week Low | $4.53 | $6.55 |
| 52 Week High | $68.00 | $14.76 |
Technical Indicators
Market Signals| Indicator | FOFO | DXR |
|---|---|---|
| Relative Strength Index (RSI) | 33.64 | 38.98 |
| Support Level | $5.56 | $11.87 |
| Resistance Level | $6.14 | $12.90 |
| Average True Range (ATR) | 0.50 | 0.63 |
| MACD | 0.09 | -0.22 |
| Stochastic Oscillator | 16.82 | 12.00 |
Price Performance
Historical ComparisonAbout FOFO Hang Feng Technology Innovation Co. Ltd. Ordinary Shares
Hang Feng Technology Innovation Co Ltd is committed to providing comprehensive corporate management consulting and asset management services, tailored to address the specific needs of each client. Its goal is to empower its clients to design, implement, and achieve their unique business and investment objectives. Its business consists of two main segments: (i) corporate management consulting services and (ii) asset management services. The corporate management consulting services include Management consulting, and Regulatory compliance and governance consulting.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.